CO4700454A1 - Medicamentos en calidad de kappa-opiatagonistas para el tra- tamiento de enfermedades inflamatorias del intestino - Google Patents

Medicamentos en calidad de kappa-opiatagonistas para el tra- tamiento de enfermedades inflamatorias del intestino

Info

Publication number
CO4700454A1
CO4700454A1 CO96034158A CO96034158A CO4700454A1 CO 4700454 A1 CO4700454 A1 CO 4700454A1 CO 96034158 A CO96034158 A CO 96034158A CO 96034158 A CO96034158 A CO 96034158A CO 4700454 A1 CO4700454 A1 CO 4700454A1
Authority
CO
Colombia
Prior art keywords
hal
opiatagonist
kappa
intestine
treatment
Prior art date
Application number
CO96034158A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Barber
Christoph Seyfried
Gerd Bartoszyk
Gottschlich
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO4700454A1 publication Critical patent/CO4700454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CO96034158A 1995-06-28 1996-06-28 Medicamentos en calidad de kappa-opiatagonistas para el tra- tamiento de enfermedades inflamatorias del intestino CO4700454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19523502A DE19523502A1 (de) 1995-06-28 1995-06-28 Kappa-Opiatagonisten für entzündliche Darmerkrankungen

Publications (1)

Publication Number Publication Date
CO4700454A1 true CO4700454A1 (es) 1998-12-29

Family

ID=7765475

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96034158A CO4700454A1 (es) 1995-06-28 1996-06-28 Medicamentos en calidad de kappa-opiatagonistas para el tra- tamiento de enfermedades inflamatorias del intestino

Country Status (26)

Country Link
US (2) US5776972A (enExample)
EP (1) EP0752246B1 (enExample)
JP (2) JP4415075B2 (enExample)
KR (1) KR100501612B1 (enExample)
CN (1) CN1119147C (enExample)
AR (1) AR004671A1 (enExample)
AT (1) ATE214275T1 (enExample)
AU (1) AU708699B2 (enExample)
BR (1) BR9602915A (enExample)
CA (1) CA2179955C (enExample)
CO (1) CO4700454A1 (enExample)
CZ (1) CZ289805B6 (enExample)
DE (2) DE19523502A1 (enExample)
DK (1) DK0752246T3 (enExample)
ES (1) ES2171577T3 (enExample)
HU (1) HU226976B1 (enExample)
NO (1) NO309674B1 (enExample)
PL (1) PL185537B1 (enExample)
PT (1) PT752246E (enExample)
RU (1) RU2190401C2 (enExample)
SI (1) SI0752246T1 (enExample)
SK (1) SK283497B6 (enExample)
TR (1) TR199600497A2 (enExample)
TW (1) TW430557B (enExample)
UA (1) UA51615C2 (enExample)
ZA (1) ZA965480B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239154B1 (en) 1996-03-08 2001-05-29 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
US6303611B1 (en) * 1996-03-08 2001-10-16 Adolor Corporation Kappa agonist compounds and pharmaceutical formulations thereof
US5763445A (en) 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
CN1104239C (zh) * 1996-12-02 2003-04-02 杏林制药株式会社 新颖的n-取代的吡咯烷衍生物及其制备方法
AU7133098A (en) * 1997-04-30 1998-11-24 Warner-Lambert Company Kappa opioid agonists
US5760023A (en) * 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP2003526594A (ja) * 1997-07-14 2003-09-09 アドラー コーポレーション カッパ・アゴニスト抗掻痒薬学的製剤およびそれにより掻痒を治療する方法
DE19827633A1 (de) * 1998-04-20 1999-10-21 Merck Patent Gmbh Verfahren zur Herstellung von enantiomerenreinem N-Methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamid
DE10116978A1 (de) * 2001-04-05 2002-10-10 Merck Patent Gmbh Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase
US20050176746A1 (en) 2002-05-17 2005-08-11 Frank Weber Use of compounds that are effective as selective opiate receptor modulators
WO2004039785A1 (en) * 2002-11-01 2004-05-13 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
DE10259245A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
US7642274B2 (en) 2003-07-04 2010-01-05 Santen Pharmaceutical Co., Ltd. Inhibitor of pain threshold decrease
EP1642590A4 (en) * 2003-07-04 2009-05-13 Santen Pharmaceutical Co Ltd MEANS TO INHIBIT THE DEGRADATION OF THE PAIN LIMIT
JP2007509865A (ja) * 2003-10-30 2007-04-19 ティオガ ファーマシュウティカルズ,インコーポレイテッド 神経障害の治療における選択的オピエート受容体調節物質の使用
US7160902B2 (en) * 2003-11-14 2007-01-09 Adolor Corporation Amide derivatives and methods of their use
CN101677997B (zh) 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
KR101773331B1 (ko) 2012-03-05 2017-08-31 닥터 레디스 레보러터리즈 리미티드 카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
WO2015114660A1 (en) * 2014-01-24 2015-08-06 Cadila Healtchare Limited Novel heterobicyclic compounds as kappa opioid agonists
EP3558300B1 (en) 2016-12-21 2021-11-24 Tioga Pharmaceuticals, Inc. Solid pharmaceutical formulations of asimadoline
WO2019122361A1 (en) 2017-12-22 2019-06-27 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Asimadoline for use in treating pulmonary diseases, vascular diseases, and sepsis
EP3932390A1 (en) 2020-07-02 2022-01-05 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical gel formulation containing asimadoline

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663343A (en) * 1985-07-19 1987-05-05 Warner-Lambert Company Substituted naphthalenyloxy-1,2-diaminocyclohexyl amide compounds
US5232978A (en) * 1988-12-23 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung 1-(2-arylethyl)-pyrrolidines
DE4034785A1 (de) * 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
CA2021817C (en) * 1989-07-24 2000-09-26 William J. Mork Upholstered article of furniture with interchangeable seating module
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide

Also Published As

Publication number Publication date
KR970000230A (ko) 1997-01-21
SK84396A3 (en) 1997-04-09
CA2179955C (en) 2008-10-07
DE59608861D1 (de) 2002-04-18
US5776972A (en) 1998-07-07
ES2171577T3 (es) 2002-09-16
NO962720L (no) 1996-12-30
CN1119147C (zh) 2003-08-27
PT752246E (pt) 2002-09-30
TW430557B (en) 2001-04-21
HU226976B1 (en) 2010-04-28
CN1145781A (zh) 1997-03-26
PL314996A1 (en) 1997-01-06
JPH0920659A (ja) 1997-01-21
JP4415075B2 (ja) 2010-02-17
CZ186696A3 (en) 1997-01-15
SK283497B6 (sk) 2003-08-05
ZA965480B (en) 1997-01-27
AR004671A1 (es) 1999-03-10
PL185537B1 (pl) 2003-05-30
JP2008201794A (ja) 2008-09-04
NO962720D0 (no) 1996-06-27
RU2190401C2 (ru) 2002-10-10
DE19523502A1 (de) 1997-01-02
TR199600497A2 (tr) 1997-01-21
BR9602915A (pt) 1998-04-22
EP0752246A2 (de) 1997-01-08
AU5616296A (en) 1997-01-09
NO309674B1 (no) 2001-03-12
HUP9601798A1 (hu) 1998-03-30
AU708699B2 (en) 1999-08-12
SI0752246T1 (en) 2002-10-31
DK0752246T3 (da) 2002-05-13
CZ289805B6 (cs) 2002-04-17
CA2179955A1 (en) 1996-12-29
KR100501612B1 (ko) 2005-10-12
EP0752246B1 (de) 2002-03-13
JP5308056B2 (ja) 2013-10-09
ATE214275T1 (de) 2002-03-15
EP0752246A3 (de) 1997-02-26
US5977161A (en) 1999-11-02
UA51615C2 (uk) 2002-12-16

Similar Documents

Publication Publication Date Title
DK1091745T3 (da) Behandling af hyperproliferative forstyrrelser
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
CY1111787T1 (el) Χορηγηση μεσων για την αγωγη φλεγμονης
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
GT200000193A (es) Prevencion de ruptura de placa por inhibidores acat.
EA200401056A1 (ru) Комбинация, содержащая производные тропана, полезные в терапии
AR037973A1 (es) 4-arilquinazolinas
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
NO20033546L (no) 4-fluor-N-indan-2-yl-benzamid og dets anvendelse som legemiddel
FI971412A7 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasie n estäjinä
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
AR004671A1 (es) Nuevos compuestos en calidad de kappa-opiatagonistas y composiciones farmaceuticas que los contienen
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
UY28360A1 (es) Nuevos compuestos
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
BRPI0408689B8 (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
DK78995A (da) Anvendelse af visse substituerede arylalkylaminer til fremstilling af et lægemiddel med neurobeskyttende virkning
FR2368278A1 (fr) Nouveaux medicaments antalgiques contenant des triazines 1-2-4